From Bench to Biomarker: Applications of the immunoSEQ® Assay Across the Clinical Development Pipeline
In this webinar, you will discover:
Immunosequencing, the science of profiling T- and B-cell receptors, has broad utility across the clinical development spectrum. Adaptive Biotechnologies’ quantitative immunoSEQ® Technology can answer early, preclinical questions about drug candidate selection, dosing, and effective drug combinations. At the clinical trial stage, the immunoSEQ Assay can also help to confirm drug safety and efficacy, establish biomarker endpoints, optimize patient selection, predict responses to therapy, and monitor for adverse events. This webinar will use real-world data to demonstrate how immunosequencing can be used at various points in the drug development and clinical research process to improve the development of new therapies.
What You Will Learn
- T-cell receptor (TCR) and B-cell receptor (BCR) sequencing data generated by Adaptive’s immunoSEQ Technology, which has been used extensively in preclinical and clinical pipelines from early drug discovery to biomarker endpoints
- How the immunoSEQ Assay can be leveraged to study drug candidate selection, optimize dosing, determine smart drug combinations, select biomarker endpoints, optimize patient selection, predict response to therapy and monitor for adverse events
- Adaptive Biotechnologies offers an end-to-end immunosequencing solution that can assist with every stage of the development pipeline from early experimental design work to advanced data analysis
immunoSEQ is For Research Use Only. Not for use in diagnostic procedures.
Patrick Raber, PhD
Following the presentation we will have a live Q&A with the following panelists:
Catherine Sanders, MT, PhD
Kellie Howard, PhD
Ned Sherry, MPH
Register for SEQdiscovery
To access these videos and all SEQdiscovery content.
If you have previously registered and opted to have an account please log in above.